The authors of the aforementioned article would like to make revisions to the labels in Figure 1 as shown below. The article has been corrected online.
Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting
Share this Article
Related Content In Supportive Cancer Care
Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression
touchREVIEWS in Oncology & Haematology. 2022;18(2):152-8 DOI: https://doi.org/10.17925/OHR.2022.18.2.152
Chemotherapy-induced myelosuppression has long been considered a toxicity that limits the dose of cytotoxic agents, which contributes to significant morbidity and mortality.1 Sub-optimal dose intensity may decrease the efficacy of therapy, thereby compromising progression-free survival (PFS) and overall survival (OS) benefits.2 Chemotherapy-induced myelosuppression is often managed with granulocyte-colony stimulating factors (G-CSFs) and erythropoiesis-stimulating agents (ESAs) […]
Foreword – touchREVIEWS in Oncology & Haematology – VOLUME 18 ISSUE 1 – 2022
Welcome to the latest edition of touchREVIEWS in Oncology & Haematology. Despite the success of the human papillomavirus vaccination programme, cervical cancer remains one of the most common cancers in women, and advanced disease carries a poor prognosis. Lebreton et al. review data from the KEYNOTE-826 Phase III trial, which showed the benefits of adding pembrolizumab […]
Foreword – touchREVIEWS in Oncology & Haematology – VOLUME 17 ISSUE 2 – 2021
touchREVIEWS in Oncology & Haematology - 2021;17(2):55
Welcome to the winter edition of touchREVIEWS in Oncology & Haematology. Despite the continued impact of the COVID-19 pandemic on cancer care, 2021 has seen important advances in many areas of oncology, which is reflected in our diverse range of articles. We begin with one of our popular expert interviews, in which Axel Merseburger discusses the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!